Loading…
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2026
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2026 | $5.9B | $1.6B | $782M | $972M | 10.9% | 8.7% | 27.3% |
| 2025 | $5.5B | $1.4B | $615M | $778M | 9.3% | 6.2% | 62.5% |
| 2024 | $5.1B | $1.4B | $378M | $613M | 6.0% | 13.3% | 253.5% |
| 2023 | $4.5B | $1.3B | $107M | $395M | 1.8% | - | - |
| 2022 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Total Revenue | - | 4,536.27 | 5,138.70 | 5,459.50 | 5,935.90 |
| Operating Revenue | - | 4,536.27 | 5,138.70 | 5,459.50 | 5,935.90 |
| Cost Of Revenue | - | 2,555.54 | 2,920.50 | 3,056.80 | 3,309.40 |
| Gross Profit | - | 1,980.73 | 2,218.20 | 2,402.80 | 2,626.50 |
| Operating Expense | - | 1,189.14 | 1,356 | 1,441.90 | 1,520.60 |
| Research And Development | - | 98.48 | 103.70 | 107.60 | 112.90 |
| Selling General And Administration | - | 1,090.66 | 1,252.30 | 1,334.30 | 1,407.70 |
| Total Expenses | - | 3,744.68 | 4,276.50 | 4,498.70 | 4,830 |
| Operating Income | - | 791.59 | 862.20 | 960.90 | 1,105.90 |
| Total Operating Income As Reported | - | 791.10 | 836.10 | 866.60 | 1,101.80 |
| EBITDA | - | 1,344 | 1,412.40 | 1,358.70 | 1,594.50 |
| Normalized EBITDA | - | 1,344.48 | 1,438.40 | 1,452.90 | 1,598.60 |
| EBIT | - | 791.10 | 847.20 | 882.50 | 1,108 |
| Interest Income | 6.28 | - | 11 | 8.40 | 9.80 |
| Interest Expense | - | 110.84 | 144.40 | 86.30 | 60.70 |
| Net Interest Income | - | -110.84 | -133.40 | -77.90 | -50.90 |
| Other Non Operating Income Expenses | -27.81 | - | - | 7.40 | -3.50 |
| Other Income Expense | - | -0.48 | -26 | -86.80 | -7.60 |
| Interest Income Non Operating | 6.28 | - | 11 | 8.40 | 9.80 |
| Interest Expense Non Operating | - | 110.84 | 144.40 | 86.30 | 60.70 |
| Net Non Operating Interest Income Expense | - | -110.84 | -133.40 | -77.90 | -50.90 |
| Pretax Income | - | 680.27 | 702.80 | 796.20 | 1,047.30 |
| Tax Provision | - | 124.07 | 149.50 | 184.70 | 262.20 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.09 | -5.54 | -21.85 | -1.03 |
| Net Income Continuous Operations | - | 556.20 | 553.30 | 611.60 | 785.10 |
| Net Income From Continuing And Discontinued Operation | - | 107.03 | 378.30 | 614.70 | 782.30 |
| Net Income From Continuing Operation Net Minority Interest | - | 557.41 | 551.50 | 610.20 | 782.30 |
| Net Income | - | 107.03 | 378.30 | 614.70 | 782.30 |
| Net Income Common Stockholders | - | 107.03 | 378.20 | 614.60 | 782.30 |
| Net Income Including Noncontrolling Interests | - | 105.81 | 380.10 | 616.10 | 785.10 |
| Normalized Income | - | 557.81 | 571.96 | 682.55 | 785.37 |
| Diluted NI Availto Com Stockholders | - | 107.03 | 378.20 | 614.60 | 782.30 |
| Basic Average Shares | - | 99.71 | 98.79 | 98.58 | 98.20 |
| Diluted Average Shares | - | 100.25 | 99.36 | 99.07 | 98.70 |
| Reconciled Depreciation | - | 552.90 | 565.20 | 476.20 | 486.50 |
| Reconciled Cost Of Revenue | - | 2,555.54 | 2,920.50 | 3,056.80 | 3,309.40 |
| Total Unusual Items | - | -0.48 | -26 | -94.20 | -4.10 |
| Total Unusual Items Excluding Goodwill | - | -0.48 | -26 | -94.20 | -4.10 |
| Minority Interests | - | 1.22 | -1.80 | -1.40 | -2.80 |
| Net Income Discontinuous Operations | - | -450.38 | -173.20 | 4.50 | 0 |
| Special Income Charges | - | -0.48 | -26 | -94.20 | -4.10 |
| Gain On Sale Of Business | - | 0 | 0 | 7.42 | - |
| Other Special Charges | - | - | - | 48.20 | - |
| Impairment Of Capital Assets | 0 | 490.56 | - | - | - |
| Restructuring And Mergern Acquisition | - | 0.48 | 26 | 46 | 4.10 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| STERIS plcthis co. | STE | $20.7B | 26.48↑ premium | 2.88 | 10.9% | 14.02 |
| Mettler-Toledo International Inc. | MTD | $23.9B | 27.44 | - | -3676.8% | 20.87 |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| West Pharmaceutical Services, Inc. | WST | $22.4B | 45.41 | 7.06 | 15.5% | 28.40 |
| Quest Diagnostics Incorporated | DGX | $21.7B |
| - |
| - |
| - |
| - |
| 21.88 |
| 3.03 |
| 13.8% |
| 12.88 |
| Labcorp Holdings Inc. | LH | $21.4B | 24.41 | 2.48 | 10.2% | 13.61 |
| Moderna, Inc. | MRNA | $20.5B | -7.25 | 2.37 | -32.6% | -7.54 |
| Incyte Corporation | INCY | $20.2B | 15.72 | 3.91 | 24.9% | 9.75 |
| Viatris Inc. | VTRS | $18.5B | - | 1.26 | -23.9% | - |
| Peer Median | - | 21.88 | 3.03 | -6.9% | 13.24 | |